DISCUSSION
prostate
RECURRENCE, PROSTATE
To our knowledge, the present study is the first multicenter, crossover randomized study to compare The investigator assessments after PET/CT and at the end of follow-up demonstrated the superiority of The strengths of our study are its prospective, multicenter, randomized crossover design. Limitations include the lack of histopathology for most lesions. Because obtaining histopathology is often ethically questionable or medically impractical, our standard of truth was a composite based on biopsy, response to local therapy, imaging, and changes in serum PSA levels during 6 mo of follow-up, as established by an independent panel of experts. The use of the independent panel removed potential bias in determining “truth” while modeling what is done in “real-life” practice.In this work, we found that 62-y-old patient with history of PCa (International Society of Urological Pathology grade 3; PSA level of 5.7 ng/mL), initially treated with prostatectomy (pT3N0R0), prostate bed radiation therapy, and 6 mo of androgen deprivation therapy (ADT), presenting with PSA recurrence (0.72 ng/mL). 